Pathological complete response and sphincter-sparing surgery after neoadjuvant radiochemotherapy with regional hyperthermia for locally advanced rectal cancer compared with radiochemotherapy alone
/in Colorectal Cancer, Hyperthermia, International Publications /von 2012-09-24 / Int J Hyperthermia 2012;28(8):707-14Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma
/in Dendritic Cells, Hepatocellular Carcinoma, International Publications /von 2012-09-11 / Int. J. Oncol. 2012 Nov;41(5):1601-9Two avirulent, lentogenic strains of Newcastle disease virus are cytotoxic for some human pancreatic tumor lines in vitro
/in International Publications, Newcastle Disease Virus, Pancreatic Cancer /von 2012-09-10 / JOP 2012 Sep;13(5):502-13Autologous dendritic cell vaccine for estrogen receptor (ER)/progestin receptor (PR) double-negative breast cancer
/in Breast Cancer, Dendritic Cells, International Publications /von 2012-09-01 / Cancer Immunol Immunother 2012 Sep;61(9):1415-24Immunotherapy in ovarian cancer
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2012-08-21 / Hum Vaccin Immunother 2012 Sep;8(9):1179-91NK cells: key to success of DC-based cancer vaccines?
/in Dendritic Cells, International Publications /von 2012-08-20 / Oncologist 2012;17(10):1256-70The use of oncolytic viruses to overcome lung cancer drug resistance
/in International Publications, Newcastle Disease Virus /von 2012-08-19 / Curr Opin Virol 2012 Oct;2(5):629-35Morphologic evidence of anti-tumor specificity of T cells activated by denritic cells derived from peripheral blood mononuclear cells of thyroid cancer patients
/in Dendritic Cells, International Publications, Thyroid Cancer /von 2012-08-10 / Korean J. Physiol. Pharmacol. 2012 Aug;16(4):243-7Dendritic cell vaccine modified by Ag85A gene enhances anti-tumor immunity against bladder cancer
/in Dendritic Cells, International Publications, Urothelial Carcinoma /von 2012-08-09 / Int. Immunopharmacol. 2012 Nov;14(3):252-60
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de